Coadministration of Oligomeric Hyaluronic Acid-Modified Liposomes with Tumor-Penetrating Peptide-iRGD Enhances the Antitumor Efficacy of Doxorubicin against Melanoma
Internalization
Penetration (warfare)
DOI:
10.1021/acsami.6b13738
Publication Date:
2016-12-25T03:24:08Z
AUTHORS (6)
ABSTRACT
A safe and efficient tumor-targeting strategy based on oligomeric hyaluronic acid (HA) modification coadministration of tumor-penetrating peptide-iRGD was successfully developed. In this study, common liposomes (cLip) were modified by HA to obtain HA-Lip. After injection into rats, HA-Lip showed good stealth in the bloodstream lower liver distribution compared with cLip. Moreover, our could be internalized B16F10 cells (CD44-overexpressing tumor cells) through HA-CD44 interaction. systemic administration melanoma-bearing mice, an increased due prolonged blood circulation time enhanced penetration retention effect. When coadministered iRGD, significantly enhanced, which promote internalization tumors located deep regions receptor-mediated endocytosis. Furthermore, doxorubicin (DOX)-loaded coadministering iRGD much better antitumor effect DOX-loaded cLip combination iRGD. toxicity test, decrease cardiotoxicity myelosuppression DOX. Taken together, results demonstrated that HA-modified a promising treatment for targeted therapy melanoma.
SUPPLEMENTAL MATERIAL
Coming soon ....
REFERENCES (70)
CITATIONS (61)
EXTERNAL LINKS
PlumX Metrics
RECOMMENDATIONS
FAIR ASSESSMENT
Coming soon ....
JUPYTER LAB
Coming soon ....